Foam products developer also selected to present four posters at Bio 2005

Ness Ziona, Israel, June 8, 2005 --- Foamix Ltd. ( www.foamix.co.il), a developer of alcohol-free, non-inflammable, stable foam products for the dermatology, gynecology, cosmetics, cosmeceuticals, wound healing and burn care markets, announced today that the Company has been awarded a speaking platform at the Bio Business Forum at Bio International 2005 in Philadelphia. The presentation, by CEO Dr. Dov Tamarkin, will take place on Tuesday, 6/21/2005 at 04:00 PM in Room A, Pennsylvania Convention Center (1101 Arch Street). Dr. Tamarkin will update attendees on recent progress and plans for the future.

"Foamix is the only company that offers foam technology for license by other pharma clients. Therefore, our message to pharma is - you provide the active, and we'll provide the complementary foam," said Foamix CEO Dr. Dov Tamarkin.

"Our technology is widely applicable and is attractive to the medical community due to its innovative nature. As foams enhance ease of use and compliance by the consumer, they command a strong premium over the same active sold as a cream or an ointment. This generates increased revenues for the producer. We look forward to seeing you in Philadelphia," said COO Mr. Meir Eini.

Foamix also announced today that the Company has been selected to present four posters at Bio International. Foamix CEO Dr. Dov Tamarkin will present the following posters at the times listed below:

PERMETHRIN 1% FOAM - A SAFE AND EFFECTIVE -
MOST CONVENIENT ANTI-LICE TREATMENT
Drug Delivery, Tuesday, June 21, from 1300-1600

A USABILITY STUDY REVEALS: -
FOAM IS SUPERIOR TO CREAMS AND OINTMENTS
Pharmaceuticals, Wednesday, June 22, from 0900-1200

INNOVATIVE ANTIFUNGAL TERBINAFINE FOAM
Pharmaceuticals, Wednesday, June 22, from 0900-1200

NOVEL MUPIROCIN FOAM FOR SKIN INFECTIONS
Pharmaceuticals, Wednesday, June 22, from 0900-1200

Bio participants are also invited to visit the Foamix team at the Company booth, Number 349.

About Foamix

Headquartered in Ness Ziona, Israel, Foamix Ltd. develops alcohol-free, non-inflammable, stable foam products for prescription, Over-the-Counter and cosmetic uses. Such uses include dermatology, gynecology, cosmetics, cosmeceuticals, wound healing and burn care. Foamix foams provide controlled delivery of state-of-the-art active ingredients. They are also able to enhance intradermal delivery of actives, for optimal effect. The Company's development capabilities range from initial development of foam formulations to scale-up, GMP manufacturing and clinical supplies. The Company was founded in January 2003 by CEO Dr. Dov Tamarkin, COO Mr. Meir Eini and Chief Technology Officer Dr. Doron Friedman. The Company employs 22 people and has 22 patents pending, out of which, two have recently been granted in the US. Foamix Ltd. is a privately held company funded by private investors. For additional information: www.foamix.co.il.

For additional information: Marjie Hadad, Media Liaison, Marjie@foamix.co.il or +972-54-536-5220.